The Vetr crowd Monday upgraded their rating for Editas Medicine Inc EDIT, from 4 stars (Buy), issued 313 days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.
Editas has traded fairly sporadically over the course of March, which began with the stock entering a trough of over 18 percent to a low of $20.40.
The stock rallied back above $26 with a mid-month announcement the company was entering an R&D partnership with Allergan plc Ordinary Shares AGN, but fell back below $22.50 shortly after when it reported an offering of 4 million shares of common stock valued at $22.50.
Learn how crowdsourced ratings could help you time the market.
Curretnly, the vetr crowd's average target price for Editas is up at $27.14, which is still below the average analyst target price of $33.50. Less than 2 percent of Vetr users are holding EDIT in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
